Including MCC or potentially other tumor types in the differential diagnosis for PSMA-avid lesions in patients with the appropriate clinical history and disease distribution could influence the decision to biopsy indeterminate lesions, potentially changing the course of treatment. The gene discussed is FOLH1; the disease is neoplasm.